UK Health Cost Body Backs Roche Drug In Incurable Blood Cancer - Wall Street Journal
MSN News UKUK Health Cost Body Backs Roche Drug In Incurable Blood CancerWall Street JournalVX) medicine MabThera in patients with the common blood cancer, follicular lymphoma, the Swiss drug maker said Tuesday. After months of consideration, the National Institute for Health and Clinical Excellence, or NICE, is recommending use of MabThera, ...NICE Recommends MabThera� (Rituximab) As First-Line Maintenance Treatment For ...Medical News Today (press release)NICE backs Roche drug as maintenance therapyReuters UKRuling may benefit cancer patientsMSN News UKall 9 news articles��
Blog Content
Post a Comment